Qube Research & Technologies LTD Immunovant, Inc. Transaction History

Qube Research & Technologies LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$30.27 - $43.79 $5.71 Million - $8.26 Million	188,689 Added 596.04%	220,346 $7.12 Million
Q4 2023 Feb 13, 2024	BUY	$31.31 - $44.19 $991,180 - $1.4 Million	31,657 New	31,657 $1.33 Million
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $119,591 - $199,908	-35,382 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$5.06 - $8.77 $179,032 - $310,300	35,382 New	35,382 $195,000
Q3 2021 Nov 12, 2021	SELL	$7.01 - $11.37 $262,545 - $425,840	-37,453 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$9.4 - $16.85 $352,058 - $631,083	37,453 New	37,453 $396,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.